Your browser doesn't support javascript.
loading
Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy.
Holmström, Morten Orebo; Novotny, Guy W; Petersen, Jesper; Aaboe-Jørgensen, Mia; Hasselbalch, Hans Carl; Andersen, Mads H; Nielsen, Signe Ledou; Fassi, Daniel El; Schöllkopf, Claudia.
Afiliação
  • Holmström MO; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Novotny GW; National Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark.
  • Petersen J; Department of Hematology, Herlev University Hospital, Herlev, Denmark.
  • Aaboe-Jørgensen M; Department of Hematology, Herlev University Hospital, Herlev, Denmark.
  • Hasselbalch HC; National Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark.
  • Andersen MH; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Nielsen SL; Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Fassi DE; National Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark.
  • Schöllkopf C; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Leuk Lymphoma ; 60(13): 3296-3299, 2019 12.
Article em En | MEDLINE | ID: mdl-31256699

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Policitemia Vera / Calreticulina / Janus Quinase 2 / Mielofibrose Primária Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Policitemia Vera / Calreticulina / Janus Quinase 2 / Mielofibrose Primária Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article